Chronic heart failure: β-blockers and pharmacogenetics

European Journal of Clinical Pharmacology

Volumn 65, Issue 1, 2009, Pages 3-17

  Azuma, Junichi ^a   Nonen, Shinpei ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

blockers; Adrenergic; Chronic heart failure; Pharmacogenetics; Polymorphism

Indexed keywords

ADRENALIN; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CATECHOLAMINE RECEPTOR; ISOPRENALINE; METOPROLOL; WARFARIN;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEART FAILURE; HUMAN; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CHRONIC DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; G-PROTEIN-COUPLED RECEPTOR KINASES; HEART FAILURE; HUMANS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PATIENT SELECTION; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, ADRENERGIC, BETA; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 57849091646     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0566-7     Document Type: Review

References (121)

1. K Swedberg J Cleland H Dargie H Drexler F Follath M Komajda L Tavazzi OA Smiseth A Gavazzi A Haverich A Hoes T Jaarsma J Korewicki S Levy C Linde JL Lopez-Sendon MS Nieminen L Pierard WJ Remme 2005 Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology Eur Heart J 26 1115 1140
2. SA Hunt 2005 ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J Am Coll Cardiol 46 e1 e82
3. Heart Failure Society of America (2006) Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 12:10-38
4. CIBIS-II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9-13
5. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007
6. M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM Gilbert NH Shusterman 1996 The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S carvedilol heart failure study group. N Engl J Med 334 1349 1355
7. M Packer AJ Coats MB Fowler HA Katus H Krum P Mohacsi JL Rouleau M Tendera A Castaigne EB Roecker MK Schultz DL DeMets 2001 Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 1651 1658
8. GZ Feuerstein TL Yue HY Cheng RR Ruffolo 1993 Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity J Hypertens (Suppl 11) S41 S48
9. MR Bristow 2000 Beta-adrenergic receptor blockade in chronic heart failure Circulation 101 558 569
10. PA Poole-Wilson K Swedberg JG Cleland A Di Lenarda P Hanrath M Komajda J Lubsen B Lutiger M Metra WJ Remme C Torp-Pedersen A Scherhag A Skene 2003 Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 7 13
11. F Follath JG Cleland W Klein R Murphy 1998 Etiology and response to drug treatment in heart failure J Am Coll Cardiol 32 1167 1172
12. T Yamada M Fukunami M Ohmori K Iwakura K Kumagai N Kondoh T Minamino E Tsujimura T Nagareda K Kotoh 1993 Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint J Am Coll Cardiol 21 628 633
13. EJ Eichhorn CM Heesch RC Risser L Marcoux B Hatfield 1995 Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol J Am Coll Cardiol 25 154 162
14. Global Technology Centre Health Research Institute. Personalized medicine: the emerging pharmacogenomics revolution. http://www.pwc.com/ techforecast/pdfs/pharmaco-wb-x.pdf. Accessed 15 Feb 2005
15. M Meadows 2005 FDA approves heart drug for black patients FDA Consum 39 8 9
16. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. www.cypalleles.ki.se
17. M Ingelman-Sundberg SC Sim A Gomez C Rodriguez-Antona 2007 Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 496 526
18. S Raimundo C Toscano K Klein J Fischer EU Griese M Eichelbaum M Schwab UM Zanger 2004 A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects Clin Pharmacol Ther 76 128 138
19. WM Cai DM Nikoloff RM Pan J de Leon P Fanti M Fairchild WH Koch PJ Wedlund 2006 CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing Pharmacogenomics J 6 343 350
20. Y Ikenaga T Fukuda K Fukuda Y Nishida M Naohara H Maune J Azuma 2005 The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution Drug Metab Pharmacokinet 20 113 116
21. UM Zanger S Raimundo M Eichelbaum 2004 Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn Schmiedebergs Arch Pharmacol 369 23 37
22. C Rodriguez-Antona M Ingelman-Sundberg 2006 Cytochrome P450 pharmacogenetics and cancer Oncogene 25 1679 1691
23. LD Bradford 2002 CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 229 243
24. AK Daly 2003 Pharmacogenetics of the major polymorphic metabolizing enzymes Fundam Clin Pharmacol 17 27 41
25. M Ingelman-Sundberg 2005 Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity Pharmacogenomics J 5 6 13
26. CG Regardh G Johnsson 1980 Clinical pharmacokinetics of metoprolol Clin Pharmacokinet 5 557 569
27. MS Lennard JH Silas S Freestone LE Ramsay GT Tucker HF Woods 1982 Oxidation phenotype-a major determinant of metoprolol metabolism and response N Engl J Med 307 1558 1560
28. J Huang SK Chuang CL Cheng ML Lai 1999 Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes Clin Pharmacol Ther 65 402 407
29. H Wuttke T Rau R Heide K Bergmann M Bohm J Weil D Werner T Eschenhagen 2002 Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects Clin Pharmacol Ther 72 429 437
30. I Zineh AL Beitelshees A Gaedigk JR Walker DF Pauly K Eberst JS Leeder MS Phillips CA Gelfand JA Johnson 2004 Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension Clin Pharmacol Ther 76 536 544
31. R Fux K Morike AM Prohmer U Delabar M Schwab E Schaeffeler G Lorenz CH Gleiter M Eichelbaum KT Kivisto 2005 Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study Clin Pharmacol Ther 78 378 387
32. G Neugebauer P Neubert 1991 Metabolism of carvedilol in man Eur J Drug Metab Pharmacokinet 16 257 260
33. A Ohno Y Saito N Hanioka H Jinno M Saeki M Ando S Ozawa J Sawada 2004 Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol Drug Metab Dispos 32 235 239
34. M Honda W Toyoda T Shimizu I Horiuchi Y Kayano M Taguchi T Nozawa H Inoue Y Hashimoto 2007 UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese Drug Metab Pharmacokinet 22 382 386
35. Y Takekuma T Takenaka K Yamazaki K Ueno M Sugawara 2007 Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity Biol Pharm Bull 30 2146 2153
36. Y Takekuma T Takenaka M Kiyokawa K Yamazaki H Okamoto A Kitabatake H Tsutsui M Sugawara 2007 Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis Biol Pharm Bull 30 537 542
37. HG Oldham SE Clarke 1997 In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol Drug Metab Dispos 25 970 977
38. T Giessmann C Modess U Hecker M Zschiesche P Dazert C Kunert-Keil R Warzok G Engel W Weitschies I Cascorbi HK Kroemer W Siegmund 2004 CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects Clin Pharmacol Ther 75 213 222
39. WH Frishman 1998 Carvedilol N Engl J Med 339 1759 1765
40. Y Horikiri T Suzuki M Mizobe 1998 Pharmacokinetics and metabolism of bisoprolol enantiomers in humans J Pharm Sci 87 289 294
41. Y Horikiri T Suzuki M Mizobe 1998 Stereoselective metabolism of bisoprolol enantiomers in dogs and humans Life Sci 63 1097 1108
42. OE Brodde 1993 Beta-adrenoceptors in cardiac disease Pharmacol Ther 60 405 430
43. OE Brodde MC Michel 1999 Adrenergic and muscarinic receptors in the human heart Pharmacol Rev 51 651 690
44. MR Bristow R Ginsburg W Minobe RS Cubicciotti WS Sageman K Lurie ME Billingham DC Harrison EB Stinson 1982 Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts N Engl J Med 307 205 211
45. K Kiuchi RP Shannon K Komamura DJ Cohen C Bianchi CJ Homcy SF Vatner DE Vatner 1993 Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure J Clin Invest 91 907 914
46. S Engelhardt M Bohm E Erdmann MJ Lohse 1996 Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure J Am Coll Cardiol 27 146 154
47. P Ping T Anzai M Gao HK Hammond 1997 Adenylyl cyclase and G protein receptor kinase expression during development of heart failure Am J Physiol 273 H707 H717
48. M Ungerer G Parruti M Bohm M Puzicha A DeBlasi E Erdmann MJ Lohse 1994 Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart Circ Res 74 206 213
49. M Ungerer M Bohm JS Elce E Erdmann MJ Lohse 1993 Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart Circulation 87 454 463
50. AM Feldman AE Cates WB Veazey RE Hershberger MR Bristow KL Baughman WA Baumgartner C Van Dop 1988 Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart J Clin Invest 82 189 197
51. J Neumann W Schmitz H Scholz L von Meyerinck V Doring P Kalmar 1988 Increase in myocardial Gi-proteins in heart failure Lancet 2 936 937
52. M Bohm P Gierschik KH Jakobs B Pieske P Schnabel M Ungerer E Erdmann 1990 Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy Circulation 82 1249 1265
53. OE Brodde 2008 Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses Pharmacol Ther 117 1 29
54. Shin J, Johnson JA (2008) Beta-blocker pharmacogenetics in heart failure. Heart Fail Rev, published online: 24 April 2008
55. DA Rathz KM Brown LA Kramer SB Liggett 2002 Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking J Cardiovasc Pharmacol 39 155 160
56. MC Levin S Marullo O Muntaner B Andersson Y Magnusson 2002 The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation J Biol Chem 277 30429 30435
57. DA Mason JD Moore SA Green SB Liggett 1999 A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor J Biol Chem 274 12670 12674
58. SA Green J Turki M Innis SB Liggett 1994 Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties Biochemistry 33 9414 9419
59. SA Green G Cole M Jacinto M Innis SB Liggett 1993 A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor J Biol Chem 268 23116 23121
60. S Nonen H Okamoto M Akino Y Matsui Y Fujio M Yoshiyama Y Takemoto J Yoshikawa J Azuma A Kitabatake 2005 No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population Br J Clin Pharmacol 60 414 417
61. KM Small SL Forbes FF Rahman KM Bridges SB Liggett 2000 A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors J Biol Chem 275 23059 23064
62. A Maqbool AS Hall SG Ball AJ Balmforth 1999 Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay Lancet 353 897
63. S Podlowski K Wenzel HP Luther J Muller P Bramlage G Baumann SB Felix A Speer R Hetzer K Kopke MR Hoehe G Wallukat 2000 Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med 78 87 93
64. SS Joseph JA Lynham AA Grace WH Colledge AJ Kaumann 2004 Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1- adrenoceptors Br J Pharmacol 142 51 56
65. J Mialet Perez DA Rathz NN Petrashevskaya HS Hahn LE Wagoner A Schwartz GW Dorn SB Liggett 2003 Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure Nat Med 9 1300 1305
66. F Rochais JP Vilardaga VO Nikolaev M Bunemann MJ Lohse S Engelhardt 2007 Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol J Clin Invest 117 229 235
67. M Borjesson Y Magnusson A Hjalmarson B Andersson 2000 A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure Eur Heart J 21 1853 1858
68. SG Terra KK Hamilton DF Pauly CR Lee JH Patterson KF Adams RS Schofield BS Belgado JA Hill JM Aranda HN Yarandi JA Johnson 2005 Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy Pharmacogenet Genomics 15 227 234
69. Y Magnusson MC Levin R Eggertsen E Nystrom R Mobini M Schaufelberger B Andersson 2005 Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy Clin Pharmacol Ther 78 221 231
70. L Chen D Meyers G Javorsky D Burstow P Lolekha M Lucas AB Semmler SM Savarimuthu KM Fong IA Yang J Atherton AJ Galbraith WA Parsonage P Molenaar 2007 Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol Pharmacogenet Genomics 17 941 949
71. SB Liggett J Mialet-Perez S Thaneemit-Chen SA Weber SM Greene D Hodne B Nelson J Morrison MJ Domanski LE Wagoner WT Abraham JL Anderson JF Carlquist HJ Krause-Steinrauf LC Lazzeroni JD Port PW Lavori MR Bristow 2006 A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure Proc Natl Acad Sci USA 103 11288 11293
72. P de Groote N Helbecque N Lamblin X Hermant E Mc Fadden C Foucher-Hossein P Amouyel J Dallongeville C Bauters 2005 Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure Pharmacogenet Genomics 15 137 142
73. HL White RA de Boer A Maqbool D Greenwood DJ van Veldhuisen R Cuthbert SG Ball AS Hall AJ Balmforth 2003 An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study Eur J Heart Fail 5 463 468
74. JC Dewar AP Wheatley A Venn JF Morrison J Britton IP Hall 1998 Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population Clin Exp Allergy 28 442 448
75. JA Johnson SG Terra 2002 Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics Pharm Res 19 1779 1787
76. KM Small DW McGraw SB Liggett 2003 Pharmacology and physiology of human adrenergic receptor polymorphisms Annu Rev Pharmacol Toxicol 43 381 411
77. SL Kirstein PA Insel 2004 Autonomic nervous system pharmacogenomics: a progress report Pharmacol Rev 56 31 52
78. K Leineweber R Buscher H Bruck OE Brodde 2004 Beta-adrenoceptor polymorphisms Naunyn Schmiedebergs Arch Pharmacol 369 1 22
79. OE Brodde K Leineweber 2005 Beta2-adrenoceptor gene polymorphisms Pharmacogenet Genomics 15 267 275
80. P Molenaar SM Savarimuthu D Sarsero L Chen AB Semmler A Carle I Yang S Bartel D Vetter I Beyerdorfer EG Krause AJ Kaumann 2007 (-)-Adrenaline elicits positive inotropic, lusitropic, and biochemical effects through beta2 -adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling Naunyn Schmiedebergs Arch Pharmacol 375 11 28
81. J Turki JN Lorenz SA Green ET Donnelly M Jacinto SB Liggett 1996 Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice Proc Natl Acad Sci USA 93 10483 10488
82. BD Hoit DP Suresh L Craft RA Walsh SB Liggett 2000 Beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals Am Heart J 139 537 542
83. H Bruck K Leineweber R Buscher A Ulrich J Radke PA Insel OE Brodde 2003 The Gln27Glu beta2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo Pharmacogenetics 13 59 66
84. G Gratze J Fortin R Labugger A Binder P Kotanko B Timmermann FC Luft MR Hoehe F Skrabal 1999 Beta-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians Hypertension 33 1425 1430
85. DM Kaye B Smirk C Williams G Jennings M Esler D Holst 2003 Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure Pharmacogenetics 13 379 382
86. OE Brodde R Buscher R Tellkamp J Radke S Dhein PA Insel 2001 Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors Circulation 103 1048 1050
87. LE Wagoner LL Craft B Singh DP Suresh PW Zengel N McGuire WT Abraham TC Chenier GW Dorn SB Liggett 2000 Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure Circ Res 86 834 840
88. SB Liggett LE Wagoner LL Craft RW Hornung BD Hoit TC McIntosh RA Walsh 1998 The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure J Clin Invest 102 1534 1539
89. JN Cohn TB Levine MT Olivari V Garberg D Lura GS Francis AB Simon T Rector 1984 Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure N Engl J Med 311 819 823
90. CR Benedict B Shelton DE Johnstone G Francis B Greenberg M Konstam JL Probstfield S Yusuf 1996 Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction SOLVD investigators. Circulation 94 690 697
91. L Hein JD Altman BK Kobilka 1999 Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission Nature 402 181 184
92. S Minatoguchi H Ito K Ishimura H Watanabe Y Imai M Koshiji K Asano S Hirakawa H Fujiwara 1995 Modulation of noradrenaline release through presynaptic alpha 2-adrenoceptors in congestive heart failure Am Heart J 130 516 521
93. KM Small LE Wagoner AM Levin SL Kardia SB Liggett 2002 Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure N Engl J Med 347 1135 1142
94. M Metra C Zani L Covolo S Nodari N Pezzali U Gelatti F Donato G Nardi L Dei Cas 2006 Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study Eur J Heart Fail 8 131 135
95. V Regitz-Zagrosek B Hocher M Bettmann M Brede K Hadamek C Gerstner HB Lehmkuhl R Hetzer L Hein 2006 Alpha2C-adrenoceptor polymorphism is associated with improved event-free survival in patients with dilated cardiomyopathy Eur Heart J 27 454 459
96. MT Lobmeyer Y Gong SG Terra AL Beitelshees TY Langaee DF Pauly RS Schofield KK Hamilton J Herbert Patterson KF Adams JA Hill JM Aranda JA Johnson 2007 Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure Pharmacogenet Genomics 17 277 282
97. WJ Koch HA Rockman P Samama RA Hamilton RA Bond CA Milano RJ Lefkowitz 1995 Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor Science 268 1350 1353
98. SJ Matkovich A Diwan JL Klanke DJ Hammer Y Marreez AM Odley EW Brunskill WJ Koch RJ Schwartz GW Dorn 2006 Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling Circ Res 99 996 1003
99. RT Premont WJ Koch J Inglese RJ Lefkowitz 1994 Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases J Biol Chem 269 6832 6841
100. WJ Koch 2004 Genetic and phenotypic targeting of beta-adrenergic signaling in heart failure Mol Cell Biochem 263 5 9
101. SB Liggett S Cresci RJ Kelly FM Syed SJ Matkovich HS Hahn A Diwan JS Martini L Sparks RR Parekh JA Spertus WJ Koch SL Kardia GW Dorn 2008 A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure Nat Med 14 510 517
102. International HapMap Project. http://www.hapmap.org/index.html.en
103. G Eisenhofer 2001 The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines Pharmacol Ther 91 35 62
104. M Suwa Y Otake A Moriguchi T Ito Y Hirota K Kawamura I Adachi I Narabayashi 1997 Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy Am Heart J 133 353 358
105. S Nonen H Okamoto Y Fujio Y Takemoto M Yoshiyama T Hamaguchi Y Matsui J Yoshikawa A Kitabatake J Azuma 2008 Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy Pharmacogenomics J 8 78 84
106. B Rigat C Hubert F Alhenc-Gelas F Cambien P Corvol F Soubrier 1990 An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels J Clin Invest 86 1343 1346
107. K Nakai C Itoh Y Miura K Hotta T Musha T Itoh T Miyakawa R Iwasaki K Hiramori 1994 Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese Circulation 90 2199 2202
108. DM McNamara R Holubkov K Janosko A Palmer JJ Wang GA MacGowan S Murali WD Rosenblum B London AM Feldman 2001 Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure Circulation 103 1644 1648
109. P de Groote N Helbecque N Lamblin X Hermant P Amouyel C Bauters J Dallongeville 2004 Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure Eur J Heart Fail 6 17 21
110. J Lopez-Sendon K Swedberg J McMurray J Tamargo AP Maggioni H Dargie M Tendera F Waagstein J Kjekshus P Lechat C Torp-Pedersen 2004 Expert consensus document on beta-adrenergic receptor blockers Eur Heart J 25 1341 1362
111. MJ Lohse S Engelhardt T Eschenhagen 2003 What is the role of beta-adrenergic signaling in heart failure? Circ Res 93 896 906
112. DS Feldman CA Carnes WT Abraham MR Bristow 2005 Mechanisms of disease: beta-adrenergic receptors-alterations in signal transduction and pharmacogenomics in heart failure Nat Clin Pract Cardiovasc Med 2 475 483
113. N Hayata Y Fujio Y Yamamoto T Iwakura M Obana M Takai T Mohri S Nonen M Maeda J Azuma 2008 Connective tissue growth factor induces cardiac hypertrophy through Akt signaling Biochem Biophys Res Commun 370 274 278
114. N Koitabashi M Arai S Kogure K Niwano A Watanabe Y Aoki T Maeno T Nishida S Kubota M Takigawa M Kurabayashi 2007 Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis Hypertension 49 1120 1127
115. Assessment of Beta-Blocker Treatment in Japanese Patients with Chronic Heart Failure. http://poppy.ac/j-chf/
116. Dreifus C (2008) A conversation with Arno Motulsky: a genetics pioneer sees a bright future, cautiously. http://www.nytimes.com/2008/04/29/science/ 29conv.html?ex=1367121600&en=68232da8922b0f7d&ei=5124&partner= permalink&exprod=permalink. The New York Times April 29
117. JL Anderson BD Horne SM Stevens AS Grove S Barton ZP Nicholas SF Kahn HT May KM Samuelson JB Muhlestein JF Carlquist 2007 Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 2563 2570
118. G Tucker 2004 Pharmacogenetics-expectations and reality BMJ 329 4 6
119. MM Hopkins D Ibarreta S Gaisser CM Enzing J Ryan PA Martin G Lewis S Detmar ME van den Akker-van Marle AM Hedgecoe P Nightingale M Dreiling KJ Hartig W Vullings T Forde 2006 Putting pharmacogenetics into practice Nat Biotechnol 24 403 410
120. M Schmedders J van Aken G Feuerstein R Kollek 2003 Individualized pharmacogenetic therapy: a critical analysis Community Genet 6 114 119
121. MR Taylor 2007 Pharmacogenetics of the human beta-adrenergic receptors Pharmacogenomics J 7 29 37